Chemists from ETH Zurich have found a way to produce poorly soluble proteins by caging a uniquely reactive boron compound.
Boron agents termed GluBs, developed by Science Tokyo researchers, have overcome a key limitation in cancer therapy by entering tumor cells through a pathway that standard drugs cannot use. The GluBs ...
Boron agents termed GluBs, developed by Science Tokyo researchers, overcome a key limitation in cancer therapy by entering tumor cells through a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results